Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-BR-1-GM and Pembrolizumab in Metastatic Breast Cancer
NCT04418219Phase 2Withdrawn
- Sponsor
- Thomas Jefferson University
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of SV-BR-1-GM in breast cancer, sponsored by Thomas Jefferson University. Planned start Dec 2020; status: withdrawn.
02
Drugs
SV-BR-1-GM
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04418219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418219.